STOCK TITAN

Agilent Technologies Inc - A STOCK NEWS

Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.

Agilent Technologies Inc (A) delivers cutting-edge analytical instruments and laboratory solutions for scientific advancement across biopharmaceutical, diagnostic, and environmental sectors. This page provides investors and industry professionals with a centralized source for all official company announcements and market-relevant developments.

Access real-time updates on Agilent's financial performance, strategic partnerships, product innovations, and regulatory milestones. Our curated news collection includes earnings releases, executive leadership updates, R&D breakthroughs, and industry event coverage—all essential for tracking the company's impact on life sciences and laboratory technology.

Key focus areas include advancements in genomic research tools, sustainability initiatives in lab operations, and cross-sector collaborations driving scientific discovery. Bookmark this page to stay informed about Agilent's evolving role in enabling precision medicine, environmental testing, and next-generation materials analysis.

Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) reported revenue of $1.69 billion for Q4 2023, down 8.7% reported and 9.7% core(1) from Q4 2022. GAAP net income was $475 million; EPS was $1.62, up 32% from Q4 2022. Full fiscal year 2023 revenue was $6.83 billion, flat on a reported basis and up 1.5% core(1) year-over-year. For fiscal year 2024, revenue is expected between $6.71 billion to $6.81 billion, and non-GAAP EPS in the range of $5.44 to $5.55 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.72%
Tags
-
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) to present at Evercore ISI HealthCONx conference on Nov. 29. President and CEO, Mike McMullen, and CFO, Bob McMahon, will lead the virtual session. The webcast will be available on Agilent's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
conferences
-
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) Increases Quarterly Dividend by 5% to 23.6 Cents Per Share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
dividends
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) has received FDA approval for PD-L1 IHC 22C3 pharmDx as a diagnostic tool to identify patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma eligible for treatment with KEYTRUDA® (pembrolizumab). This marks the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval, highlighting Agilent's leadership in developing companion diagnostics for anti-PD-1 therapies. PD-L1 IHC 22C3 pharmDx also aids in identifying patients with non-small cell lung cancer, esophageal squamous cell carcinoma, cervical cancer, head and neck squamous cell carcinoma, and triple-negative breast cancer suitable for treatment with KEYTRUDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
-
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) announces Jennifer Field, an Oregon State University researcher, as the recipient of the Agilent Thought Leader Award for her pioneering work with organic micropollutants and PFAS. Dr. Field's research focuses on the quantitative analysis of PFAS compounds, known as 'forever chemicals', and their environmental implications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
-
Rhea-AI Summary
Tele2 AB (NASDAQ: TEL2 A) and (NASDAQ: TEL2 B) in partnership with Nokia, announces the delivery of a 5G private mobile network to AirForestry for controlling electric drones used in forest thinning. The pilot project, running in 2024, aims to introduce the solution into commercial forestry operations. The technology promises to revolutionize forest harvesting, offering efficient and sustainable solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
Rhea-AI Summary
Crawford & Company announces record quarterly revenue in Q3 2023, with revenues before reimbursements of $325.6 million, up 10% from the same period last year. Net income attributable to shareholders was $12.3 million, compared to a loss of $15.1 million in Q3 2022. Diluted earnings per share were $0.25 for both CRD-A and CRD-B, compared to a diluted loss per share of $(0.31) in the prior year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
-
Rhea-AI Summary
Crawford & Company has announced the election of Fred R. Donner as an independent director, effective November 3, 2023. With almost 40 years of experience in the insurance industry, Mr. Donner brings expertise in leading and advising corporations through restructurings, international expansion, risk management, and capital market transactions. His addition to the board strengthens the company's commitment to leveraging deep industry expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
management
-
Rhea-AI Summary
Crawford & Company (NYSE: CRD-A and CRD-B) has declared a quarterly dividend of $0.07 per share on the Class A Common Stock and $0.07 per share on the Class B Common Stock. The dividend will be payable on December 1, 2023, to shareholders of record as of November 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
dividends
Rhea-AI Summary
Agilent Technologies to release Q4 fiscal year 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
Agilent Technologies Inc

NYSE:A

A Rankings

A Stock Data

29.22B
284.18M
0.29%
91.65%
1.2%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
SANTA CLARA